Evidence map›Paper›PMID 41406937›Full record

Trial reportCell reports. Medicine2025

CfDNA-based copy-number dynamics during anti-PD1 treatment in metastatic triple negative breast cancer.

Aaron Y Lin, Olga I Isaeva, Teoman Deger, Veerle C M Geurts, Daan C L Vessies, Leonie Voorwerk, Maarten Slagter, Kat S Moore, Paul van der Leest, John W M Martens and 3 more

Registry-linked trialAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02499367 (Adaptive Phase II Randomized Non-comparative Trial of Nivolumab After Induction Treatment in Triple-negative Breast Cancer), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02499367 phase2unknown statusnot on this map

Adaptive Phase II Randomized Non-comparative Trial of Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients: TONIC-trial

TypeinterventionalSponsorThe Netherlands Cancer InstituteRan2015 to 2025Enrolled84ConditionsBreast CancerArmsNivolumab, Radiation therapy, Low dose doxorubicin, Cyclophosphamide, Cisplatin
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Aaron Y LinDivision of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Olga I IsaevaDivision of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Teoman DegerDepartment of Medical Oncology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Veerle C M GeurtsDivision of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Daan C L VessiesDepartment of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Leonie VoorwerkDivision of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Internal Medicine, Groene Hart Ziekenhuis, Gouda, the Netherlands.
Maarten SlagterDepartment of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Kat S MooreDivision of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Paul van der LeestDepartment of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, the Netherlands.
John W M MartensDepartment of Medical Oncology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Daan van den BroekDepartment of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Lodewyk F A WesselsDivision of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Marleen KokDivision of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: m.kok@nki.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell-free DNA (cfDNA) is an emerging technology to predict and monitor response to cancer treatment, including immune checkpoint blockade (ICB). However, data on cfDNA dynamics during ICB in metastatic triple negative breast cancer (mTNBC) are limited. While most applications of cfDNA involve assays that focus on mutation detection, mTNBC and multiple other cancer types are driven by copy-number alterations (CNAs). We evaluate cfDNA-based copy-number profile abnormality (CPA) score as a potential biomarker for monitoring ICB response in mTNBC, analyzing data from 87 patients enrolled in stage 1 and stage 2 of the TONIC trial. We find significant concordance between cfDNA-based and tissue-based CNA profiles. Additionally, responders show a decrease in CPA scores upon ICB at week 6 (three cycles of nivolumab). These findings underscore the potential of cfDNA-based CNA dynamics as a non-invasive biomarker for ICB early response assessment in patients with mTNBC. The TONIC trial is registered at ClinicalTrial.gov (NCT02499367).

Indexed as

Cell-Free Nucleic AcidsDNA Copy Number VariationsImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorTriple Negative Breast NeoplasmsAdultAgedBiomarkers, TumorFemaleHumansMiddle AgedNeoplasm MetastasisNivolumabBiomarkers, TumorCell-Free Nucleic AcidsImmune Checkpoint InhibitorsNivolumabPDCD1 protein, humanProgrammed Cell Death 1 Receptorcell-free DNAcirculating tumor DNAcopy number alterationscopy number profile abnormality scoreimmune checkpoint blockadeliquid biopsyshallow whole-genome sequencingTONIC trial (NCT02499367)triple negative breast cancer

Identifiers

PMID41406937
PMCPMC12765946

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.